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Introduction
The epithelial–mesenchymal transition (EMT) was origi-
nally defined by developmental biologists as a morphologi-
cal conversion occurring at specific sites in embryonic
epithelia to give rise to individual migratory cells [1]. EMT
is a fundamental process in the development of most
metazoans and is primarily involved in the shaping of
embryos. In mammals, EMT has been associated with the
formation of the parietal endoderm [2]. It is also directly
involved in the formation of the mesoderm and definitive
endoderm at the primitive streak during gastrulation [3].
Neural crest cells emerge from the dorsal neural epithe-
lium through EMT before undergoing extensive migration
and differentiation into many derivatives [4]. EMT has also
been implicated in the ontogeny of other structures includ-
ing somites and heart endocardium [5].
Although EMT was recognized in the late nineteenth
century, it is only recently that some of the molecular
mechanisms in the developing embryo have been
revealed. Most current studies are performed in vitro with
epithelial cell lines, which can be converted into fibroblast-
like cells under specific culture conditions. However, not
all normal or malignant cell lines share all characteristics
with embryonic epithelia. In many instances, epithelial cell
lines can be refractory to EMT, perhaps owing to the inac-
cessibility of scatter factors or to intrinsic inhibitory mech-
anisms. Conversely, culture conditions do not always
allow epithelial cells to achieve full polarity and can facili-
tate dispersion. The definition of an EMT, and the require-
ments to execute one, in vitro are at variance with those
in vivo and therefore cannot exactly recapitulate these
events. It is therefore not surprising to find studies differ-
ing in their stringency for the various criteria for defining an
EMT.
The current criteria for defining an EMT in vitro [1,6]
involve the loss of epithelial cell polarity, the separation
into individual cells and subsequent dispersion after the
acquisition of cell motility. EMT presumably involves the
disassembly of tight junctions, adherens junctions and
desmosomes as well as the reorganization of cell sub-
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Abstract
The epithelial–mesenchymal transition (EMT) is a developmental mechanism of crucial importance in
establishing the body plan in many multicellular organisms. Several transduction pathways controlling
the various steps of the morphological transition have been identified by molecular analyses of this
process in cell lines and in vivo. The newly formed mesenchymal cells can exhibit locomotory and
invasive phenotypes, suggesting that EMTs contribute to the progression of carcinoma. Diverse
evidence indicates that EMT subprograms are involved in the appearance of different breast carcinoma
types. Several normal and malignant breast cell lines are currently being analyzed to define key steps in
EMT and to identify candidate genes. DNA profiling technology is also being applied to uncover
pathways that lead to a metastatic phenotype.
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strate adhesion complexes. After the loss of cell polarity,
the cytoskeleton is significantly remodeled. A shift from
cytokeratin intermediate filaments to vimentin is consid-
ered to be an important criterion for EMT, although
vimentin is not necessarily a reliable marker of mesenchy-
mal cells (transcription of the vimentin gene is particularly
sensitive to serum components). The epithelial and mes-
enchymal phenotypes also show particular transcription
profiles including cytoskeletal components and extracellu-
lar matrix components. It is likely that several other types of
protein will be found to be associated with EMT in only
one of the two states. This minireview addresses the ques-
tion of whether EMT can be involved in breast cancer pro-
gression and whether these tumor types can benefit from
a molecular understanding of EMT [7].
EMT signal transduction pathways
EMT can be induced in vitro in several epithelial cell lines
by growth factors activating tyrosine kinase surface recep-
tors. These factors include scatter factor/hepatocyte
growth factor, fibroblast growth factors, epithelial growth
factor (EGF) family members, and insulin-like growth
factors 1 and 2 [7]. For instance the human 184 breast
cell line can respond to EGF [8]. In most cases the
Ras/mitogen-activated protein kinase (MAPK) pathway
has a crucial role in inducing EMT, but in some cell lines
the transient activation of Src, phosphoinositide 3-kinase
(PI3K) and Rac has an effect on particular aspects of
EMT. At least two normal breast cell lines (NMuMG and
EpH4: two normal murine mammary cell lines) and other
lines respond specifically to transforming growth factor-β
(TGF-β), although one of them (the EpH4 line) undergoes
EMT when expressing the oncogenic H-Ras [9–11].
MAPK and PI3K have also been implicated in TGF-β sig-
naling and more direct signalling, both through the con-
ventional Smad pathways and other as yet unknown
pathways [12]. These signaling pathways, and particularly
the cooperativity between Ras and TGF-β signalling, are
also observed in the EMT process in squamous carcinoma
of the skin, which can progressively acquire a fibroblast-
like morphology in later stages of the disease [13]. The
classical TGF-β signaling pathway leading to inhibition of
cell growth or even the induction of apoptosis is abro-
gated by activated Ras in part through Raf/MAPK or PI3K
activation. In addition, it has been clearly shown in the skin
carcinogenesis model that nuclear accumulation of
Smad2 by oncogenic Ras is required for progression
towards the spindle cell carcinoma stage.
ECM components, including collagens and laminin 5, can
also induce EMT in some cell lines [14]. Current research
is aimed at identifying gene targets within these pathways.
One class of potential targets is the metalloproteases,
which are important in morphogenesis. Their function in
mammary gland branching morphogenesis [15,16] and
tumor formation has been described recently [17]. Inter-
estingly, only the expression of stromelysin 1 (matrix metal-
loprotease [MMP]-3) in the Scp2 mammary cell line is suf-
ficient to induce EMT in vitro and tumorigenesis in vivo
[18]. The targeted expression of MMP3 in the mammary
gland can induce premalignant and malignant lesions,
forming poorly differentiated tumors with a fibroblast-like
morphology in a proportion of the carcinoma cells [19].
These data suggest that EMT is involved in early or later
steps of breast malignancy development. However, breast
malignancies are a heterogeneous group of different mor-
phological entities. Pathological characteristics of breast
carcinomas need to be defined so that the phenotype can
be correlated with the molecular alterations observed
in vitro or in animal models.
Pathological characteristics of breast
malignancies
Epithelial tumors (carcinomas) are the most frequent type
of breast tumor. The first step in the histological study of
breast carcinomas is to determine whether the tumor is
confined to the glandular component of the organ (in situ
carcinoma) or whether it invades the stroma (invasive car-
cinoma). Then, the histological subtype within each cate-
gory is determined and prognostic indicators such as
stage, grade and the presence of vascular invasion are
assessed. The stage of the tumor is evaluated according
to its size and the presence of axillary lymph node metas-
tases. The grade of a carcinoma is an estimation of its dif-
ferentiation.
The grading of breast carcinomas is based solely on the
invasive portion of the tumor. The grading procedure
involves a three-tiered system for describing the tumor
structure. The first criterion is the evaluation of tubule for-
mation. The absence of tubules with only cord sheets and
isolated cells might reflect an incomplete EMT process.
The second criterion is the nuclear grade assessed by
comparison with the sizes of nuclei in normal cell and
between carcinoma cells. The third criterion is the mitotic
count expressed as the number of mitoses per 10 high-
magnification fields [20].
The term invasive carcinoma encompasses numerous enti-
ties differing from each other by morphological character-
istics related to the degree of differentiation and the
organization of the cells.
The most common form (75% of cases) is ductal invasive
carcinoma. The cells can grow in irregular or rounded
sheets, or nests or cords of solid clusters of cells, fre-
quently interspersed with isolated cells. The presence of
gland lumens, poorly or well formed, reflects the degree of
differentiation of the tumor. Those glands lacking myoep-
ithelial cells are not delimitated by a basement membrane.
The amount of stroma and in particular the amount of the103
inflammatory infiltrate varies considerably between individ-
ual ductal invasive carcinomas. An association with in situ
carcinoma is observed in almost 70% of cases [21–23].
The second large category of invasive carcinoma is the
group of lobular carcinomas, which account for 10–15%.
These tumors are composed of carcinoma cells, isolated
or organized in single file or narrow cords, usually with an
abundant surrounding stroma. Gland formation is not a
feature of classical infiltrative lobular carcinoma. An in situ
component is associated with this form in nearly 90% of
cases [24]. Additional patterns of infiltrative lobular carci-
nomas have been recognized: they have different architec-
tural and cytological patterns but cohesive cells. These
patterns include the solid pattern, composed of large
nests of closely packed but non-cohesive cells separated
by thin vascular channels, the alveolar pattern character-
ized by clusters of 20 cells arranged in round nests sepa-
rated by small amounts of stroma, and the pleomorphic
pattern composed of cells showing a higher degree of
nuclear atypia and more mitotic figures [23].
In addition to the ductal and the lobular types of breast
carcinoma, other rare types have been described, each
accounting for less than 5% of the total. The group of
metaplastic carcinomas is of particular interest with regard
to EMT. This is because these carcinomas are believed to
be of epithelial origin. There are two main categories: one
composed of intermixed cells with epithelial morphology
but exhibiting a glandular differentiation associated with a
squamous metaplasia, and the second composed of
epithelial cells with glandular differentiation tightly mixed
with non-epithelial cells. The non-epithelial cells are com-
posed of spindle shape cells, bone and cartilaginous cells
or both. The spindle cells often seem to be merged with
epithelial cells, yet they represent the majority cell type
characterized by morphological heterogeneity. Cytokeratin
and more specifically high-molecular-mass cytokeratins
and vimentin are observed within both the spindle cell and
epithelial cell components [23].
Some other rare types of breast carcinoma are associated
with a more favorable clinical outcome. These are gener-
ally well-differentiated tumors such as tubular carcinoma
composed of angular glands lined by a single layer of
cylindrical cells; mucinous carcinoma, a tumor that pro-
duces large amounts of extracellular mucus; and cribriform
carcinoma composed of large clusters of cells with glan-
dular differentiation [25]. Some other lesions show an
undifferentiated morphology. An example is the medullary
carcinoma characterized by large syncytial sheets of large
cells with atypical nuclei and high rates of mitosis, mixed
with an abundant inflammatory stroma [26].
This non-exhaustive overview of the pathology of breast
carcinomas illustrates the broad diversity of the morpho-
logical aspects of breast tumors. This diversity is in part
related to the differentiation state of the carcinoma cells.
The prognosis is evaluated from the pathological type, the
stage and the grade of its tumor and this is used to deter-
mine the individual therapeutic scheme. Unfortunately, the
evaluation of prognosis is still inaccurate. A better knowl-
edge of the EMT pathways and of the genes involved in
breast carcinomas might be of great value in improving our
understanding of these tumors and consequently allowing
a more reliable prognosis for patients.
Involvement of EMT in breast carcinoma
Loss of heterozygosity at 16q22.1 is relatively frequent in
breast carcinoma, implicating E-cadherin as a tumor sup-
pressor gene. E-cadherin, the prototype type 1 epithelial
cadherin, has been studied extensively in EMT. In vivo,
E-cadherin is downregulated specifically at sites of EMT
such as gastrulation in Drosophila and in several verte-
brates including the mouse. Numerous studies have
described a partial or complete loss of E-cadherin during
carcinoma progression, which is correlated with an unfa-
vorable prognosis [27,28] and confirming that E-cadherin
is a caretaker of the epithelial state. Several distinct mech-
anisms of E-cadherin downregulation have been
described. Mutations have been found in the E-cadherin
gene in about 50% of lobular carcinomas of the breast
[29]. Most mutations lead to non-functional proteins. In
accordance with the Knudson two-hit hypothesis, most of
these mutations are found in tumors with loss of heterozy-
gosity (LOH) of the E-cadherin wild-type locus. A recent
study examined in depth whether the two-hit hypothesis
applies to sporadic ductal invasive carcinoma of the
breast [30]. No mutations were found in this series, con-
firming previous studies. However, LOH in the E-cadherin
locus was not significantly associated with hypermethyla-
tion in the other allele, suggesting the existence of other
mechanisms for E-cadherin gene extinction.
Genetic screening in Drosophila led to the identification of
snail, a gene involved in the control of gastrulation [31].
snail transcripts are specifically expressed in invaginating
mesodermal cells just before their EMT. Snail and a
closely related member of this zinc finger transcriptional
repressor, named Slug, have also been found in verte-
brates. There is convincing evidence that Slug is required
for gastrulation and neural crest emigration in Xenopus
and in the chick embryo, and that Snail has a similar role in
the mouse [32]. The important discovery was made that
Snail can downregulate transcription of the E-cadherin
gene through its interaction with E boxes in the proximal
region of the promoter [33]. Slug can also bind to the
same region of the promoter, although with lower affinity
(A Cano, personal communication). Other transcription
factors also inhibit the transcription of E-cadherin genes:
an example is the zinc finger protein SIP1, a downstream
target gene in the TGF-β-mediated induction of EMT in the
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NMuMG cell line [34]. Snail expression has been analyzed
by  in situ hybridization in breast carcinomas and com-
pared with that of E-cadherin. Snail is expressed mostly in
dedifferentiated tumors and is correlated with grading. In
heterogeneous tumors, Snail is expressed in carcinoma
cell islands devoid of E-cadherin. It is found in all ductal
invasive carcinomas with lymph node involvement.
However, Snail was not found in the small number of
lobular carcinomas investigated by Blanco et al. [35].
Another study reports Snail expression in tumors in which
the E-cadherin promoter is hypermethylated rather than in
tumors with LOH in the E-cadherin locus [30]. Another
recent study analyzed the roles of the various E boxes in
the control of E-cadherin transcription: the findings stress
the importance of E-box C and thus are at variance with
previous studies. In addition, in breast cell lines, Slug
expression is more tightly correlated than Snail with a lack
of E-cadherin expression [36].
Clearly there is a need for more extensive analysis of
breast tumor samples, but significant progress has already
been made toward understanding one key aspect of EMT
in breast cancers. The phenotype of breast cancer
micrometastases in lymph nodes and in the bone marrow
suggests that EMT occurs within the primary tumors [37].
Furthermore, if these cells are at the origin of secondary
tumors, it would indicate that there is a potential reversal
of the phenotype because E-cadherin can be re-
expressed in the metastatic lesion, which has a generally
more differentiated phenotype than the primary tumor
[38,39]. This is indeed consistent with the notion that
E-cadherin is regulated mostly by epigenetic mechanisms.
It also suggests that LOH at one locus, together with a
mutation or a definitive extinction of transcription at the
other locus, explains only a small fraction of all breast car-
cinomas.
There are several breast carcinoma fibroblast-like lines
that express the classical type 1 N-cadherin [40] and pos-
sibly some type 2 cadherins. The expression of N-cadherin
de novo in breast carcinoma cells induces an EMT [41].
The mechanism by which N-cadherin can overcome the
maintenance of the epithelial state by E-cadherin is not
known, although a domain in N-cadherin essential for this
effect has been identified [42]. E-cadherin can be down-
regulated by other mechanisms including the recently
described mechanism of ubiquitination and endocytosis of
E-cadherin in epithelial cells stimulated by EMT-inducing
growth factors [43].
Concluding remarks
Epithelial cell plasticity is a major feature of embryonic
development. Epithelial cell intercalation during the con-
vergence–extension movement, or during the process of
cavitation and branching morphogenesis, implies local
phenotypic changes in the cells undergoing these
processes. The development of the mammary gland prob-
ably employs these mechanisms. EMT is one of the most
drastic aspects of epithelial cell plasticity. Some of the
molecular programs of EMT might be involved in the devel-
opment of the mammary gland, particularly at terminal end
buds or possibly in lateral branching [44]. However, EMT
is also likely to be important in tumor progression. One of
the best markers of EMT associated with breast cancer is
the loss of E-cadherin, and this is controlled in part by
Snail family members, as is EMT associated with develop-
ment. Other transduction pathways might be found in the
mammary tumors in which TGF-β or tyrosine kinase
surface receptor ligands are produced.
Recent DNA chip profiling has already proved powerful for
tumor classification: a subset of breast carcinomas display
molecular markers of the basal cell phenotype [45] associ-
ated with myoepithelial cell differentiation [46]. This sub-
group has the poorest prognosis of all the groups studied
as assessed by hierarchical clustering [45]. These find-
ings do not preclude the possibility that these tumors
contain myoepithelial cells rather than carcinoma cells
with basal characteristics. A recent study shows that
murine HC11 clones with basal cell characteristics
acquire a motile phenotype in vitro and invasive properties
in vivo when exposed to EGF [47]. The plasticity of human
breast carcinoma has also been investigated in vitro by
establishing cell lines and assaying them for their tumori-
genic properties. At least one particular line has a myofi-
broblastic phenotype, suggesting the intriguing possibility
that in some cases the myofibroblasts in the stroma of
breast tumors might be derived from the carcinoma cells
[48].
A subset of genes, rather than a particular single gene,
can be used as a prognostic marker, and this approach
shows great promise for predicting metastatic outcome
[49]. Various laboratories are currently trying to identify
genes more specifically associated with EMT, tumor inva-
sion and tumor metastasis, either with cell line models or
with tumors of diverse grades and stages. It is expected
that new candidate genes will be validated in the near
future and that we will learn significantly more about the
effects of EMT on the progression of breast carcinomas.
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